{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:58:02Z","timestamp":1789408682469,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Lowy Foundation Paediatric Fellowship"},{"name":"AUSiMED"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.prrv.2018.03.002","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T14:30:42Z","timestamp":1521383442000},"page":"68-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Side effects of medications used to treat childhood interstitial lung disease"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-9095","authenticated-orcid":false,"given":"Oded","family":"Breuer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.prrv.2018.03.002_b0005","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/ppul.23183","article-title":"Childhood interstitial lung disease: a systematic review","volume":"50","author":"Hime","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0010","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2015-2725","article-title":"Interstitial lung disease in children younger than 2\u202fyears","volume":"137","author":"Spagnolo","year":"2016","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0015","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13023-017-0637-x","article-title":"Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade\u2019s experience","volume":"12","author":"Saddi","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.prrv.2018.03.002_b0020","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1750-1172-4-26","article-title":"Incidence and classification of pediatric diffuse parenchymal lung diseases in Germany","volume":"4","author":"Griese","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.prrv.2018.03.002_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-8-24","article-title":"The incidence of interstitial lung disease 1995\u20132005: a Danish nationwide population-based study","volume":"8","author":"Kornum","year":"2008","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0030","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ppul.10125","article-title":"Idiopathic interstitial pneumonitis in children: a national survey in the United Kingdom and Ireland","volume":"34","author":"Dinwiddie","year":"2002","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.prrv.2018.03.002_b0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1183\/09031936.04.00089803","article-title":"Task force on chronic interstitial lung disease in immunocompetent children","volume":"24","author":"Clement","year":"2004","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.prrv.2018.03.002_b0040","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/thoraxjnl-2015-207349","article-title":"European protocols for the diagnosis and initial treatment of interstitial lung disease in children","volume":"70","author":"Bush","year":"2015","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1016\/j.prrv.2018.03.002_b0045","first-page":"57","article-title":"Interstitial lung disease in childhood: clinical and genetic aspects","volume":"9","author":"Kitazawa","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"10.1016\/j.prrv.2018.03.002_b0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-5-22","article-title":"Interstitial lung diseases in children","volume":"5","author":"Clement","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0055","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1183\/13993003.01900-2016","article-title":"Management of children with interstitial lung diseases: the difficult issue of acute exacerbations","volume":"48","author":"Clement","year":"2016","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1164\/rccm.201305-0923ST","article-title":"An Official American Thoracic Society clinical practice guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy","volume":"188","author":"Kurland","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0065","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1042\/cs0940557","article-title":"Anti-inflammatory actions of glucocorticoids: molecular mechanisms","volume":"94","author":"Barnes","year":"1998","journal-title":"Clin Sci (Lond)"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.002_b0070","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/(SICI)1099-0496(199811)26:5<332::AID-PPUL5>3.0.CO;2-Q","article-title":"Chronic interstitial lung disease in children: response to high-dose intravenous methylprednisolone pulses","volume":"26","author":"Desmarquest","year":"1998","journal-title":"Pediatr Pulmonol"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1183\/09031936.99.14614299","article-title":"Increasing dose of methylprednisolone pulse therapy treats desquamative interstitial pneumonia in a child","volume":"14","author":"Paul","year":"1999","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3476(05)81646-4","article-title":"Sequential pulmonary function measurements during treatment of infantile chronic interstitial pneumonitis","volume":"116","author":"Kerem","year":"1990","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.002_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ppul.20114","article-title":"Pediatric interstitial lung disease revisited","volume":"38","author":"Fan","year":"2004","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.002_b0090","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaad.2016.02.1241","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.002_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: infectious complications and vaccination recommendations","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaad.2016.02.1239","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: gastrointestinal and endocrinologic side effects","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.01.062","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: a review of glucocorticoid pharmacology and bone health","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.prrv.2018.03.002_b0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1542\/pir.30-12-497","article-title":"Long-term corticosteroid use","volume":"30","author":"Brinn","year":"2009","journal-title":"Pediatr Rev"},{"issue":"12","key":"10.1016\/j.prrv.2018.03.002_b0115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJM200003233421204","article-title":"Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis","volume":"342","author":"Lai","year":"2000","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.prrv.2018.03.002_b0120","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1542\/peds.2006-2023J","article-title":"Glucocorticoid-induced osteoporosis in children: impact of the underlying disease","volume":"119","author":"Leonard","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.002_b0125","first-page":"209","article-title":"Osteoporosis due to glucocorticoid use in children with chronic illness","volume":"64","author":"Ward","year":"2005","journal-title":"Horm Res"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.002_b0130","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jaci.2013.08.040","article-title":"Glucocorticoid-induced osteoporosis: an update on effects and management","volume":"132","author":"Buehring","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.prrv.2018.03.002_b0135","first-page":"349","article-title":"Monitoring adverse reaction to steroid therapy in children","volume":"41","author":"Seth","year":"2004","journal-title":"Indian Pediatr"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0140","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/jpids\/piu055","article-title":"Screening and monitoring for infectious complications when immunosuppressive agents are studied in the treatment of autoimmune disorders","volume":"4","author":"Loechelt","year":"2015","journal-title":"J Pediatr Infect Dis Soc"},{"key":"10.1016\/j.prrv.2018.03.002_b0145","first-page":"1","article-title":"Prevention of HBV reactivation in patients treated with biologic agents","author":"Koutsianas","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0150","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/ic.1998.v26.a89371","article-title":"Prevention of infection in the immunocompromised host","volume":"26","author":"Risi","year":"1998","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.prrv.2018.03.002_b0155","series-title":"General best practice guidelines for immunization","author":"Kroger","year":"2017"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0160","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.1950180603","article-title":"Chloroquine treatment of interstitial lung disease in children","volume":"18","author":"Avital","year":"1994","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/(SICI)1099-0496(199701)23:1<55::AID-PPUL7>3.0.CO;2-O","article-title":"Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis","volume":"23","author":"Balasubramanyan","year":"1997","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.002_b0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJM200501133520223","article-title":"Hydroxychloroquine and surfactant protein C deficiency","volume":"352","author":"Rosen","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1067\/mpd.2001.114545","article-title":"Surfactant protein deficiency in familial interstitial lung disease","volume":"139","author":"Amin","year":"2001","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0180","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.22811","article-title":"Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency","volume":"49","author":"Williamson","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"11","key":"10.1016\/j.prrv.2018.03.002_b0185","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ppul.22971","article-title":"Natural history of five children with surfactant protein C mutations and interstitial lung disease","volume":"49","author":"Avital","year":"2014","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.prrv.2018.03.002_b0190","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.arbres.2012.08.005","article-title":"Is treatment with hydroxychloroquine effective in surfactant protein C deficiency?","volume":"49","author":"Rabach","year":"2013","journal-title":"Arch Bronconeumol"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0195","first-page":"233","article-title":"Chronic interstitial lung disease in children","volume":"83","author":"Paiva","year":"2007","journal-title":"J Pediatr (Rio J)"},{"issue":"2","key":"10.1016\/j.prrv.2018.03.002_b0200","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1055\/s-0033-1363687","article-title":"Neonatal respiratory insufficiency caused by an (homozygous) ABCA3-stop mutation: a systematic evaluation of therapeutic options","volume":"226","author":"Winter","year":"2014","journal-title":"Klin Padiatr"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/thoraxjnl-2016-208649","article-title":"Lung disease caused by ABCA3 mutations","volume":"72","author":"Kroner","year":"2017","journal-title":"Thorax"},{"issue":"24","key":"10.1016\/j.prrv.2018.03.002_b0210","doi-asserted-by":"crossref","first-page":"14361","DOI":"10.1074\/jbc.271.24.14361","article-title":"Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients","volume":"271","author":"Beers","year":"1996","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.prrv.2018.03.002_b0215","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3109\/08923973.2013.780078","article-title":"Chloroquine cardiomyopathy \u2013 a review of the literature","volume":"35","author":"Tonnesmann","year":"2013","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0220","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"American Academy of O. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.prrv.2018.03.002_b0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1164\/ajrccm.186.8.807","article-title":"ABCA3 transporter deficiency","volume":"186","author":"Hayes","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2018.03.002_b0230","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.rmed.2017.05.014","article-title":"Heterogeneity of lung disease associated with NK2 homeobox 1 mutations","volume":"129","author":"Nattes","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.prrv.2018.03.002_b0235","first-page":"2013","article-title":"Diffuse parenchymal lung disease caused by surfactant deficiency: dramatic improvement by azithromycin","author":"Thouvenin","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.prrv.2018.03.002_b0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13052-015-0198-3","article-title":"A disorder of surfactant metabolism without identified genetic mutations","volume":"41","author":"Montella","year":"2015","journal-title":"Ital J Pediatr"},{"issue":"6","key":"10.1016\/j.prrv.2018.03.002_b0245","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/adc.2009.171553","article-title":"Characteristics of disorders associated with genetic mutations of surfactant protein C","volume":"95","author":"Thouvenin","year":"2010","journal-title":"Arch Dis Child"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J"},{"issue":"8891","key":"10.1016\/j.prrv.2018.03.002_b0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(94)91030-8","article-title":"Ototoxicity with azithromycin","volume":"343","author":"Wallace","year":"1994","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.prrv.2018.03.002_b0260","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/ppul.21479","article-title":"Frequency, treatment, and functional outcome in children with hypersensitivity pneumonitis","volume":"46","author":"Buchvald","year":"2011","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.prrv.2018.03.002_b0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/(SICI)1099-0496(199701)23:1<49::AID-PPUL6>3.0.CO;2-K","article-title":"Idiopathic pulmonary fibrosis in infants","volume":"23","author":"Osika","year":"1997","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2018.03.002_b0270","series-title":"The Complete Drug Reference [www.medicinescomplete.com]","author":"Martindale","year":"2017"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218300460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054218300460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T18:09:54Z","timestamp":1543601394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054218300460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":54,"alternative-id":["S1526054218300460"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2018.03.002","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side effects of medications used to treat childhood interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2018.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}